Results 271 to 280 of about 3,331,587 (315)
Some of the next articles are maybe not open access.

Drug target central

Expert Opinion on Drug Discovery, 2009
One of the primary pillars of drug discovery is the drug target, its relationship to both the drugs designed against it and the biological processes in which it is involved. Here we review the informatics approaches required to build a complete catalogue of known drug targets.Using Pfizer's internal target database as a narrative, we review the steps ...
Lee, Harland, Anna, Gaulton
openaire   +2 more sources

Targeting drugs to mitochondria

European Journal of Pharmaceutics and Biopharmaceutics, 2012
Mitochondria are of an increasing interest in pharmaceutical and medical research since it has been reported that dysfunction of these organelles contributes to several diseases with a great diversity of clinical appearance. By the fact that mitochondria are located inside the cell and, in turn, origins of mitochondrial diseases or targets of drugs are
Anne, Heller   +2 more
openaire   +2 more sources

HSP60 as a Drug Target

Current Pharmaceutical Design, 2012
Heat shock proteins (HSPs) are ubiquitous and evolutionary conserved proteins induced by cell stress. HSP60, in particular, is a typical mitochondrial molecular chaperone that is known to assist nascent polypeptides to reach a native conformation. HSP60 is also known to interact with HSP10.
Hiroyuki Nakamura, Hidemitsu Minegishi
openaire   +2 more sources

RAMPs as Drug Targets

2012
The receptor activity-modifying protein (RAMP) family of membrane proteins regulates G protein-coupled receptor (GPCR) function in several ways. RAMPs can alter their pharmacology and signalling as well as the trafficking of these receptors to and from the cell surface. Accordingly, RAMPs may be exploited as drug targets, offering new opportunities for
Patrick M, Sexton   +4 more
openaire   +2 more sources

Ribonucleases as Drug Targets

Trends in Pharmacological Sciences, 2018
Across disease indications, there is immediate need for new drug targets. Target scarcity is reflected in a growing number of same-target drugs of marginal clinical value. Advances in RNA mechanisms of disease are revealing a windfall of targets for nucleic acids therapeutics. However, nucleic acids remain limited as pharmaceutical agents.
Emanuele, Canestrari, Zain, Paroo
openaire   +2 more sources

Targets for Antiinflammatory Drugs

Annual Review of Pharmacology and Toxicology, 1995
Aspirin-like nonsteroidal antiinflammatory agents, corticosteroids, and methotrexate are the mainstays of therapy in rheumatoid arthritis and other inflammatory diseases. It is now clear that these agents share at least one characteristic: All of these agents diminish the adhesive interactions required for the accumulation of white blood cells at an ...
B N, Cronstein, G, Weissmann
openaire   +2 more sources

Targeting drugs for tuberculosis

Science, 2019
Lipid-binding improves the delivery of antibiotics to cells infected with ...
Trever C, Smith, Bree B, Aldridge
openaire   +2 more sources

Nanotechonology for Drug Targeting

Advances in Science and Technology, 2010
Nanoparticles (Np) and liposomes (L) were engineered obtaining selective drug delivery systems able to cross BBB and to treat cancer diseases, respectively. The first goal was achieved conjugating a specific epta-glucopeptide (g7) to polymeric nanoparticles (Np). The data related the nociceptive activity showed the ability of g7-Np to cross the BBB and
RUOZI, Barbara   +3 more
openaire   +2 more sources

Tankyrases as drug targets

The FEBS Journal, 2013
Tankyrase 1 and tankyrase 2 are poly(ADP‐ribosyl)ases that are distinguishable from other members of the enzyme family by the structural features of the catalytic domain, and the presence of a sterile α‐motif multimerization domain and an ankyrin repeat protein‐interaction domain.
Lari, Lehtiö   +2 more
openaire   +2 more sources

Drug targeting with nanoparticles

European Journal of Drug Metabolism and Pharmacokinetics, 1994
Nanoparticles are colloidal polymeric particles (size < 1000 nm) to which drugs are bound by sorption, incorporation, or chemical binding. After intravenous injection they normally distribute into the organs of the reticuloendothelial system (liver, spleen, lungs, bone marrow). However, their body distribution can be altered by coating with surfactants
openaire   +2 more sources

Home - About - Disclaimer - Privacy